Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Lasers in Medical Science
Erschienen in: Lasers in Medical Science 5/2018

13.01.2018 | Original Article

Photodynamic antimicrobial chemotherapy (PACT) using toluidine blue inhibits both growth and biofilm formation by Candida krusei

verfasst von: Bruna Graziele Marques da Silva, Moisés Lopes Carvalho, Isabela Bueno Rosseti, Stella Zamuner, Maricilia Silva Costa

Erschienen in: Lasers in Medical Science | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Among non-albicans Candida species, the opportunistic pathogen Candida krusei emerges because of the high mortality related to infections produced by this yeast. The Candida krusei is an opportunistic pathogen presenting an intrinsic resistance to fluconazol. In spite of the reduced number of infections produced by C. krusei, its occurrence is increasing in some groups of patients submitted to the use of fluconazol for prophylaxis. Photodynamic antimicrobial chemotherapy (PACT) is a potential antimicrobial therapy that combines visible light and a nontoxic dye, known as a photosensitizer, producing reactive oxygen species (ROS) that can kill the treated cells. The objective of this study was to investigate the effects of PACT, using toluidine blue, as a photosensitizer on both growth and biofilm formation by Candida krusei. In this work, we studied the effect of the PACT, using TB on both cell growth and biofilm formation by C. krusei. PACT was performed using a light source with output power of 0.068 W and peak wavelength of 630 nm, resulting in a fluence of 20, 30, or 40 J/cm2. In addition, ROS production was determined after PACT. The number of samples used in this study varied from 6 to 8. Statistical differences were evaluated by analysis of variance (ANOVA) and post hoc comparison with Tukey-Kramer test. PACT inhibited both growth and biofilm formation by C. krusei. It was also observed that PACT stimulated ROS production. Comparing to cells not irradiated, irradiation was able to increase ROS production in 11.43, 6.27, and 4.37 times, in the presence of TB 0.01, 0.02, and 0.05 mg/mL, respectively. These results suggest that the inhibition observed in the cell growth after PACT could be related to the ROS production, promoting cellular damage. Taken together, these results demonstrated the ability of PACT reducing both cell growth and biofilm formation by C. krusei.
Literatur
1.
Morgan J, Meltzer MI, Plikaytis BD, Sofair AN, Huie-White S, Wilcox S, Harrison LH, Seaberg EC, Hajjeh RA, Teutsch SM (2005) Excess mortality, hospital stay, and cost due to candidemia: a case control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 26:540–547CrossRefPubMed
2.
3.
Pfaller MA, Diekema DJ (2010) Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 36:1–53CrossRefPubMed
4.
Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP (1998) National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn Microbiol Infect Dis 30:121–129CrossRefPubMed
5.
Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, Pallavicini FB, Viscoli C (2006) Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 6:21CrossRefPubMedPubMedCentral
6.
7.
Pemán J, Cantón E, Quindós G, Eraso E, Alcoba J, Guinea J, Merino P, Ruiz-Pérez-de-Pipaon MT, Pérez-del-Molino L, Linares-Sicilia MJ, Marco F, García J, Roselló EM, Gómez-G-de-la-Pedrosa E, Borrell N, Porras A, Yagüe G, FUNGEMYCA Study Group (2012) Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J Antimicrob Chemother 67:1181–1187CrossRefPubMed
8.
Abbas J, Bodey GP, Hanna HA, Mardani M, Girgawy E, Abi-Said D, Whimbey E, Hachem R, Raad I (2000) Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med 160:2659–2664CrossRefPubMed
9.
Muñoz P, Saánchez-Somolinos M, Alcalá L, Rodríguez-Créixems M, Peláez T, Bouza E (2005) Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. J Antimicrob Chemother 55:188–193CrossRefPubMed
10.
Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Nagy E, Dobiasova S, Rinaldi M, Barton R, Veselov A, Global Antifungal Surveillance Group (2008) Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 46:515–521CrossRefPubMed
11.
Samaranayake YH, Samaranayake LP (1994) Candida krusei: biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen. J Med Microbiol 41:295–310CrossRefPubMed
12.
Espinel-Ingroff A, Pfaller MA, Bustamante B, Canton E, Fothergill A, Fuller J, Gonzalez GM, Lass-Flörl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Szeszs MW, St-Germain G, Bonfietti LX, Guarro J, Turnidge J (2014) Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother 58:2006–2012CrossRefPubMedPubMedCentral
13.
Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R (1991) Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 325:1274–1277CrossRefPubMed
14.
Cantón E, Pemán J, Gobernado M, Viudes A, Espinel-Ingroff A (2004) Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob Agents Chemother 48:2477–2482CrossRefPubMedPubMedCentral
15.
Scorzoni L, de Lucas MP, Mesa-Arango AC, Fusco-Almeida AM, Lozano E, Cuenca-Estrella M, Mendes-Giannini MJ, Zaragoza O (2013) Antifungal efficacy during Candida krusei infection in non-conventional models correlates with the yeast in vitro susceptibility profile. PLoS One 8:e60047CrossRefPubMedPubMedCentral
16.
17.
Allison RR, Moghissi K (2013) Photodynamic therapy (PDT): PDT mechanisms. Clin Endoscopy 46:24–29CrossRef
18.
Sharma SK, Mroz P, Dai T, Huang Y-Y, St. Denis TG, Hamblin MR (2012) Photodynamic therapy for cancer and for infections: what is the difference? Isr J Chem 52:691–705CrossRefPubMedPubMedCentral
19.
20.
Wilson BC, Patterson MS (2008) The physics, biophysics and technology of photodynamic therapy. Phys Med Biol 53:R61–109CrossRefPubMed
21.
Wainwright M (1998) Photodynamic antimicrobial chemotherapy (PACT). J Antimicrob Chemother 42:13–28CrossRefPubMed
22.
Sperandio FF, Sabino CP, Vecchio D, Garcia-Diaz M, Huang L, Huang Y-Y, Hamblin MR (2015) Antimicrobial photodynamic therapy in dentistry. In: de Freitas PM, Simões A (eds) Lasers in Dentistry: Guide for Clinical Practice. John Wiley & Sons, Inc, Hoboken
23.
Maisch T (2007) Anti-microbial photodynamic therapy: useful in the future? Lasers Med Sci 22:83–91CrossRefPubMed
24.
25.
Vera DM, Haynes MH, Ball AR, Dai T, Astrakas C, Kelso MJ, Hamblin MR, Tegos GP (2012) Strategies to potentiate antimicrobial photoinactivation by overcoming resistant phenotypes. Photochem Photobiol 88:499–511CrossRefPubMedPubMedCentral
26.
27.
Huang L, Huang YY, Mroz P, Tegos GP, Zhiyentayev T, Sharma SK, Lu Z, Balasubramanian T, Krayer M, Ruzié C, Yang E, Kee HL, Kirmaier C, Diers JR, Bocian DF, Holten D, Lindsey JS, Hamblin MR (2010) Stable synthetic cationic bacteriochlorins as selective antimicrobial photosensitizers. Antimicrob Agents Chemother 54:3834–3841CrossRefPubMedPubMedCentral
28.
Calzavara-Pinton P, Rossi MT, Sala R, Venturini M (2012) Photodynamic antifungal chemotherapy. Photochem Photobiol 88:512–522CrossRefPubMed
29.
Chabrier-Roselló Y, Foster TH, Pérez-Nazario N, Mitra S, Haidaris CG (2005) Sensitivity of Candida albicans germ tubes and biofilms to photofrin-mediated phototoxicity. Antimicrob Agents Chemother 49:4288–4295CrossRefPubMedPubMedCentral
30.
31.
Demidova TN, Hamblin MR (2005) Effect of cell-photosensitizer binding and cell density on microbial photoinactivation. Antimicrob Agents Chemother 49:2329–2335CrossRefPubMedPubMedCentral
32.
Lambrechts SA, Aalders MC, Van Marle J (2005) Mechanistic study of the photodynamic inactivation of Candida albicans by a cationic porphyrin. Antimicrob Agents Chemother 49:2026–2034CrossRefPubMedPubMedCentral
33.
Lam M, Jou PC, Lattif AA, Lee Y, Malbasa CL, Mukherjee PK, Oleinick NL, Ghannoum MA, Cooper KD, Baron ED (2011) Photodynamic therapy with Pc 4 induces apoptosis of Candida albicans. Photochem Photobiol 87:904–909CrossRefPubMedPubMedCentral
34.
Souza SC, Junqueira JC, Balducci I, Koga-Ito CY, Munin E, Jorge AO (2006) Photosensitization of different Candida species by low power laser light. J Photochem Photobiol B 83:34–38CrossRefPubMed
35.
Munin E, Giroldo LM, Alves LP, Costa MS (2007) Study of germ tube formation by Candida albicans after photodynamic antimicrobial chemotherapy (PACT). J Photochem Photobiol B 88:16–20CrossRefPubMed
36.
Carvalho GG, Felipe MP, Costa MS (2009) The photodynamic effect of methylene blue and toluidine blue on Candida albicans is dependent on medium conditions. J Microbiol 47:619–623CrossRefPubMed
37.
Giroldo LM, Felipe MP, de Oliveira MA, Munin E, Alves LP, Costa MS (2009) Photodynamic antimicrobial chemotherapy (PACT) with methylene blue increases membrane permeability in Candida albicans. Lasers Med Sci 24:109–112CrossRefPubMed
38.
Prates RA, Kato IT, Ribeiro MS, Tegos GP, Hamblin MR (2011) Influence of multidrug efflux systems on methylene blue-mediated photodynamic inactivation of Candida albicans. J Antimicrob Chemother 66:1525–1532CrossRefPubMedPubMedCentral
39.
Rosseti IB, Chagas LR, Costa MS (2014) Photodynamic antimicrobial chemotherapy (PACT) inhibits biofilm formation by Candida albicans, increasing both ROS production and membrane permeability. Lasers Med Sci 29:1059–1064CrossRefPubMed
40.
Tanaka M, Kinoshita M, Yoshihara Y, Shinomiya N, Seki S, Nemoto K, Hirayama T, Dai T, Huang L, Hamblin MR, Morimoto Y (2012) Optimal photosensitizers for photodynamic therapy of infections should kill bacteria but spare neutrophils. Photochem Photobiol 88:227–232CrossRefPubMed
41.
Souza RC, Junqueira JC, Rossoni RD, Pereira CA, Munin E, Jorge AO (2010) Comparison of the photodynamic fungicidal efficacy of methylene blue, toluidine blue, malachite green and low-power laser irradiation alone against Candida albicans. Lasers Med Sci 25:385–389CrossRefPubMed
42.
Barbério GS, da Costa SV, dos Santos Silva M, de Oliveira TM, Silva TC, de Andrade Moreira Machado MA (2014) Photodynamic inactivation of Candida albicans mediated by a low density of light energy. Lasers Med Sci 29:907–910PubMed
43.
Wilson M, Mia N (1993) Sensitisation of Candida albicans to killing by low-power laser light. J Oral Pathol Med 22:354–357CrossRefPubMed
44.
Soares BM, da Silva DL, Sousa GR, Amorim JC, de Resende MA, Pinotti M, Cisalpino OS (2009) In vitro photodynamic inactivation of Candida spp. growth and adhesion to buccal epithelial cells. J Photochem Photobiol B 94:65–70CrossRefPubMed
45.
Rodrigues GB, Dias-Baruffi M, Holman N, Wainwright M, Braga GU (2013) In vitro photodynamic inactivation of Candida species and mouse fibroblasts with phenothiazinium photosensitisers and red light. Photodiagn Photodyn Ther 10:141–149CrossRef
46.
Espinel-Ingroff A, Canton E, Peman J, Rinaldi MG, Fothergill AW (2009) Comparison of 24-hour and 48-hour voriconazole MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27–A3 document) in three laboratories: results obtained with 2,162 clinical isolates of Candida spp. and other yeasts. J Clin Microbiol 47:2766–2771CrossRefPubMedPubMedCentral
47.
Ruhnke M, Rickerts V, Cornely OA, Buchheidt D, Glöckner A, Heinz W, Höhl R, Horré R, Karthaus M, Kujath P, Willinger B, Presterl E, Rath P, Ritter J, Glasmacher A, Lass-Flörl C, Groll AH (2011) Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses 54:279–310CrossRefPubMed
48.
Van de Veerdonk FL, Netea MG, Joosten LA, van der Meer JW, Kullberg BJ (2010) Novel strategies for the prevention and treatment of Candida infections: the potential of immunotherapy. FEMS Microbiol Rev 34:1063–1075CrossRefPubMed
49.
White TC, Marr KA, Bowden RA (1998) Clinical cellular and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11:382–402PubMedPubMedCentral
50.
Cannon RD, Lamping E, Holmes AR, Niimi K, Tanabe K, Niimi M, Monk BC (2007) Candida albicans drug resistance another way to cope with stress. Microbiology 153:3211–3217CrossRefPubMed
51.
52.
Uppuluri P, Chaturvedi AK, Srinivasan A, Banerjee M, Ramasubramaniam AK, Köhler JR, Kadosh D, Lopez-Ribot JL (2010) Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog 6:e1000828CrossRefPubMedPubMedCentral
53.
Ha KC, White TC (1999) Effects of azole antifungal drugs on the transition from yeast cells to hyphae in susceptible and resistant isolates of the pathogenic yeast Candida albicans. Antimicrob Agents Chemother 43:763–768PubMedPubMedCentral
54.
55.
Chandra J, Mukherjee PK, Ghannoum MA (2012) Candida biofilms associated with CVC and medical devices. Mycoses 55:46–57CrossRef
56.
Bliss JM, Bigelow CE, Foster TH, Haidaris CG (2004) Susceptibility of candida species to photodynamic effects of photofrin. Antimicrob Agents Chemother 48:2000–2006CrossRefPubMedPubMedCentral
Metadaten
Titel
Photodynamic antimicrobial chemotherapy (PACT) using toluidine blue inhibits both growth and biofilm formation by Candida krusei
verfasst von
Bruna Graziele Marques da Silva
Moisés Lopes Carvalho
Isabela Bueno Rosseti
Stella Zamuner
Maricilia Silva Costa
Publikationsdatum
13.01.2018
Verlag
Springer London
Erschienen in
Lasers in Medical Science / Ausgabe 5/2018
Print ISSN: 0268-8921
Elektronische ISSN: 1435-604X
DOI
https://doi.org/10.1007/s10103-017-2428-y

Weitere Artikel der Ausgabe 5/2018

Lasers in Medical Science 5/2018 Zur Ausgabe

Original Article

The assessment of Buerger’s exercise on dorsal foot skin circulation in patients with vasculopathic diabetic foot ulcer by using wireless near-infrared spectroscope: a cohort prospective study

Original Article

Electroretinogram evaluation for the treatment of proliferative diabetic retinopathy by short-pulse pattern scanning laser panretinal photocoagulation

Correction

Correction to: Electroretinogram evaluation for the treatment of proliferative diabetic retinopathy by short-pulse pattern scanning laser panretinal photocoagulation

Original Article

Light-emitting diode therapy (photobiomodulation) effects on oxygen uptake and cardiac output dynamics during moderate exercise transitions: a randomized, crossover, double-blind, and placebo-controlled study

Original Article

Effect of 1064-nm Q-switched Nd:YAG laser on invasiveness and innate immune response in keratinocytes infected with Candida albicans

Original Article

Outcomes of CO2 laser-assisted posterior cordectomy in bilateral vocal cord paralysis in 132 cases